Switch noninferior for patients without genotype information with viral suppression while receiving regimen containing ritonavir-boosted protease inhibitor <\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
FRIDAY, June 23, 2023 (HealthDay News) — For patients with HIV without genotype information, a second-line switch to dolutegravir is noninferior to a regimen containing a ritonavir-boosted protease inhibitor (PI), according to a study published in the June 22 issue of the New England Journal of Medicine<\/em>.<\/p>\n Loice A. Ombajo, M.B., Ch.B., from the University of Nairobi in Kenya, and colleagues conducted a prospective, open-label trial at four sites in Kenya involving patients without genotype information who had viral suppression while receiving treatment containing a ritonavir-boosted PI. Participants were randomly assigned to switch to dolutegravir or continue the current regimen (398 and 397, respectively). The primary end point was a plasma HIV type 1 RNA level of at least 50 copies\/mL at week 48.<\/p>\n The researchers found that at week 48, 5.0 and 5.1 percent of patients in the dolutegravir and ritonavir-boosted PI groups, respectively, met the primary end point, a result that met the criterion for noninferiority. At the time of treatment failure, the investigators observed no mutations conferring resistance to dolutegravir or the ritonavir-boosted PI. A similar incidence of treatment-related grade 3 or 4 events was seen in the dolutegravir and ritonavir-boosted PI groups (5.7 and 6.9 percent, respectively).<\/p>\n “This trial provides information that can inform the current distribution of treatment regimens in Kenya and other similar settings, thus enabling consideration of a transition from ritonavir-boosted PI-based regimens to a dolutegravir-based regimen in almost 75 percent of patients currently receiving second-line therapy, which would provide advantages with regard to cost, risk of toxic effects, risk of drug-drug interactions, and pill burden,” the authors write.<\/p>\n The study was funded by ViiV Healthcare, the manufacturer of dolutegravir.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n